HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michel Pellerin Raymond Martineau Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haché, M. Articles by Dupuis, J. Search for Related Content PubMed PubMed Citation Articles by Haché, M. Articles by Dupuis, J. Related Collections Cardiac - physiology Myocardial protection

J Thorac Cardiovasc Surg 2003;125:642-649
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery

From the Montreal Heart Institute, Montreal, Quebec, Canada.

Received for publication Dec 3, 2001. Accepted for publication July 16, 2002. Address for reprints: André Denault, MD, Research Center, Montreal Heart Institute, 5000 Belanger St East, Montreal, Quebec, H1T 1C8 Canada (E-mail: denault{at}videotron.ca).

Objective: Pulmonary hypertension is commonly found in patients undergoing valvular surgery and can be worsened by cardiopulmonary bypass. Inhaled epoprostenol (prostacyclin) has been used for the treatment of pulmonary hypertension, but its effects compared with those of placebo on hemodynamics, oxygenation, echocardiographic examination, and platelet function have not been studied during cardiac surgery.
Methods: Twenty patients with pulmonary hypertension undergoing cardiac surgery were randomized in a double-blind study to receive inhaled epoprostenol (60 µg) or placebo. The inhalation occurred after induction of anesthesia and before surgical incision. The effects on left and right systolic and diastolic cardiac functions evaluated by means of pulmonary artery catheterization and transesophageal echocardiography, as well as oxygenation and platelet aggregation, were studied.
Results: Inhalation of epoprostenol significantly reduced indexed right ventricular stroke work from 10.7 ± 4.57 g · m · m^-2 to 7.8 ± 3.94 g · m · m^-2 (P = .003) and systolic pulmonary artery pressure from 48.4 ± 18 mm Hg to 38.9 ± 11.9 mm Hg (P = .002). The effect was correlated with the severity of pulmonary hypertension (r = 0.76, P = .01) and was no longer apparent after 25 minutes. There was no significant effect on systemic arterial pressures, left ventricular function, arterial oxygenation, platelet aggregation, and surgical blood loss.
Conclusion: Inhaled epoprostenol reduces pulmonary pressure and improves right ventricular stroke work in patients with pulmonary hypertension undergoing cardiac surgery. A dose of 60 µg is hemodynamically safe, and its effect is completely reversed after 25 minutes. We did not observe any evidence of platelet dysfunction or an increase in surgical bleeding after administration of inhaled epoprostenol.

This article has been cited by other articles:

				P. Couture, A. Y. Denault, M. Pellerin, and J.-C. Tardif Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery: [La milrinone ameliore la fonction systolique mais non la fonction diastolique pendant la chirurgie de pontage aortocoronarien] Can J Anesth, July 1, 2007; 54(7): 509 - 522. [Abstract] [Full Text] [PDF]

				K. Subramaniam and J.-P. Yared Management of Pulmonary Hypertension in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 119 - 136. [Abstract] [PDF]

				Y. Lamarche, L. P. Perrault, S. Maltais, K. Tetreault, J. Lambert, and A. Y. Denault Preliminary experience with inhaled milrinone in cardiac surgery Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1081 - 1087. [Abstract] [Full Text] [PDF]

				A. Y. Denault, Y. Lamarche, P. Couture, F. Haddad, J. Lambert, J.-C. Tardif, and L. P. Perrault Inhaled milrinone: a new alternative in cardiac surgery? Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2006; 10(4): 346 - 360. [Abstract] [PDF]

				A. Y. Denault, P. Couture, J. Buithieu, F. Haddad, M. Carrier, D. Babin, S. Levesque, and J.-C. Tardif Left and right ventricular diastolic dysfunction as predictors of difficult separation from cardiopulmonary bypass: [La dysfonction ventriculaire diastolique gauche et droite comme predicteur des difficultes de sevrage de la circulation extracorporelle]. Can J Anesth, October 1, 2006; 53(10): 1020 - 1029. [Abstract] [Full Text] [PDF]

				Y. Lamarche, J. Gagnon, O. Malo, G. Blaise, M. Carrier, and L. P. Perrault Ventilation prevents pulmonary endothelial dysfunction and improves oxygenation after cardiopulmonary bypass without aortic cross-clamping Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 554 - 563. [Abstract] [Full Text] [PDF]

				S. Fortier, R.G. DeMaria, Y. Lamarche, O. Malo, A. Denault, F. Desjardins, M. Carrier, and L.P. Perrault Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 109 - 116. [Abstract] [Full Text] [PDF]

				C. A. Dias-Junior, A. Martineau, P. Couture, and A. Denault Pharmacologic Therapy of Acute Pulmonary Embolism * Response Anesth. Analg., January 1, 2004; 98(1): 266 - 267. [Full Text] [PDF]